Dr. Rongbo Lin 林榕波
Chief Physician
Department of Gastrointestinal Medical Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment and palliative care for gastric, colorectal, esophageal, hepatobiliary, and pancreatic malignancies, as well as AIDS-related tumors.
Dr. Lin is a Chief Physician in Abdominal Oncology. From 2012 to 2015, Dr. Lin provided medical aid at Princess Marina Hospital in Botswana. Dr. Lin has published over 30 papers in international SCI and domestic core journals, authored multiple monographs, and led or participated in several research projects.
Professional roles
- Member, CSCO Gastric Cancer Expert Committee
- Member, Tumor Targeted Therapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, National Professional Committee on Tumor Palliative Care and Humanistic Care
- Author, CSCO Gastric Cancer Diagnosis and Treatment Guidelines
Name order: in Chinese the family name comes first (Lin Rongbo). Papers usually list the name as Rongbo Lin or Lin R.
Selected publications
32 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Med, 2026 (senior author): Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer. PubMed 42421558
- J Natl Compr Canc Netw, 2026 (first author): Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial. PubMed 42119607
- Cancer Sci, 2024 (senior author): Phase I trial of apatinib and paclitaxel+oxaliplatin+5-FU/levoleucovorin for treatment-naïve advanced gastric cancer. PubMed 38354746
- Front Oncol, 2022 (senior author): Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer. PubMed 36158665
- J Natl Compr Canc Netw, 2022 (first author): Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial. PubMed 36075387
- Front Med (Lausanne), 2022 (senior author): POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. PubMed 35983099
- J Natl Compr Canc Netw, 2021 (first author): Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial. PubMed 34343968
- Ann Transl Med, 2020 (senior author): Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. PubMed 33178765
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion